The nation of Zimbabwe has turned down a substantial US healthcare agreement valued at 367 million US dollars (272 million pounds) spanning five years because of the United States' insistence on confidential data.
This move became public following a official document from December was disclosed, revealing that Head of State Emmerson Mnangagwa believed the agreement was "skewed".
A government spokesperson later clarified that the US was requesting genetic material for research and commercial purposes while refused to guarantee the benefits from any future treatments.
"We must now begin the challenging and unfortunate task of scaling back our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had donated over $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has appealed for continued negotiations to secure a agreement suitable to all parties so the nation's critical HIV treatment initiative can be sustained.
Broader Background
This development comes after a comparable case in Kenya, where a high court blocked a similar health funding agreement following legal challenges were filed about the safety of Kenyans' health data.
Since returning to office recently, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
The agency had overseen aid for the US government, but Trump stated its spending was "wasteful" and his administration was seeking government-to-government agreements to enhance transparency and responsibility.
According to statements, 16 African countries have to date agreed to similar agreements, representing over $18.3bn in new funding.
Details of the Declined Agreement
This assistance for Zimbabwe would have supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this partnership might have yielded immense advantages for Zimbabwean communities, particularly the 1.2 million currently receiving antiretroviral therapy through American-funded initiatives," Tremont said.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"Zimbabwe was being asked to share its genetic material and health information over an extended period, without any equivalent guarantee of access to any scientific breakthroughs – like new medicines or tests – that could result from that provided information," Mangwana explained.
"Effectively, our country would provide the raw materials for medical research without any certainty that the end products would be available to our people should a future health crisis arise."
National Interest and Global Health
He also noted that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were disrupting structures previously set up through the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme created to deal with potential pandemics.
"This system is intended to guarantee that when a nation provides its samples, the benefits – such as vaccines and treatments – are shared equitably, not commercialised exclusively by those with the capability to develop them."
Zimbabwe's reservations over the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We welcome continued discussions with our US partners on how future collaboration might be designed in a manner that honours the sovereignty and dignity of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it recognised the government's concerns, but recommended that negotiations should continue since much of the nation's Aids initiatives were funded by external financing.
"If specific concerns exist, such as those involving information security or agreement terms, these can frequently be addressed through detailed discussion and negotiated safeguards," it said.
This impasse emphasises the complex tensions between receiving much-needed international aid and safeguarding a country's data in an increasingly data-driven world.